Efficacy and Safety of ALL Impella Use in Japanese Patients With Drug-Resistant Acute HF: Insight From Japan J-PVAD Study
Presented by Junya Ako, MD
Junya Ako, MD, presents the interim analysis of data from 819 patients from the Japanese Registry for Percutaneous VAD (J-PVAD). J-PVAD is an investigator initiated, prospective study of ALL Impella use in Japan with the goal to safely and effectively disseminate the use of Impella with appropriate use guidance.
Dr. Ako describes the Impella site qualification and initiation process in Japan and best practices implemented in Japan. These include:
- Early identification of cardiogenic shock and use of Impella
- Pre-PCI Impella initiation
- Use of pulmonary artery catheter (PAC) and hemodynamic-guided decision making
- Minimizing use of inotropes/vasopressors
Dr. Ako reviews Impella efficacy data from Japan, highlighting 77% 30-day survival in Impella treated patients with AMI cardiogenic shock.
Dr. Ako from Kitasato University presented on behalf of the J-PVAD registry investigators.
This video is part of a series: Achieving >70% AMI-CS Survival: Best Practices From Around the World
- Achieving >70% AMI-CS Survival: Insight From National Cardiogenic Shock Initiative (William O'Neill, MD)
- Efficacy and Safety of ALL Impella Use in Japanese Patients With Drug-Resistant Acute HF: Insight From Japan J-PVAD Study (Junya Ako, MD) [current page]
- Importance of Timing and Impact of Extensive Revascularization on Long-Term Survival in Cardiogenic Shock: Insights From European Multi-Center Studies (Giuseppe Tarantini, MD, PhD)
- Closing Summation, RECOVER III, and Intro to RECOVER IV (William O'Neill, MD)
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information